July 22, 2026

Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

read more →

PRNewswire

May 26, 2026

Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout

read more →

Labiotech

July 29, 2026

Meeting unmet needs: new treatments for gout race in the clinic

read more →

San Diego Union Tribune

July 28, 2026

His father suffered from gout in silence. Now a San Diego scientist is bringing the cure home

read more →